 RANK Ligand
"RANK Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
| Descriptor ID |
D053245
|
| MeSH Number(s) |
D12.644.276.374.750.562 D12.644.276.972.562 D12.776.467.374.750.562 D12.776.467.972.562 D23.529.374.750.562 D23.529.972.562
|
| Concept/Terms |
RANK Ligand- RANK Ligand
- Osteoclast Differentiation Factor
- Differentiation Factor, Osteoclast
- Osteoprotegerin Ligand
- RANKL Protein
- Receptor Activator of Nuclear Factor-kappa B Ligand
- Receptor Activator of Nuclear Factor kappa B Ligand
- TNF Superfamily, Member 11
- TRANCE Protein
- Tumor Necrosis Factor Ligand Superfamily Member 11
- Tumor Necrosis Factor-Related Activation-Induced Cytokine
- Tumor Necrosis Factor Related Activation Induced Cytokine
- OPGL Protein
- Receptor Activator of Nuclear Factor-kappaB Ligand
- Receptor Activator of Nuclear Factor kappaB Ligand
|
Below are MeSH descriptors whose meaning is more general than "RANK Ligand".
Below are MeSH descriptors whose meaning is more specific than "RANK Ligand".
This graph shows the total number of publications written about "RANK Ligand" by people in UAMS Profiles by year, and whether "RANK Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 3 | 2 | 5 | | 2022 | 0 | 2 | 2 | | 2021 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2018 | 2 | 1 | 3 | | 2017 | 0 | 1 | 1 | | 2016 | 6 | 3 | 9 | | 2015 | 4 | 3 | 7 | | 2014 | 2 | 4 | 6 | | 2013 | 1 | 2 | 3 | | 2012 | 2 | 4 | 6 | | 2011 | 3 | 0 | 3 | | 2010 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2008 | 2 | 1 | 3 | | 2007 | 1 | 1 | 2 | | 2006 | 0 | 7 | 7 | | 2005 | 0 | 3 | 3 | | 2004 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "RANK Ligand" by people in Profiles over the past ten years.
-
Anloague A, Sabol HM, Kaur J, Khan S, Ashby C, Schinke C, Barnes CL, Alturkmani F, Ambrogini E, Gundesen MT, Lund T, Amstrup AK, Andersen TL, Diaz-delCastillo M, Roodman GD, Bellido T, Delgado-Calle J. A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. Haematologica. 2025 Apr 01; 110(4):952-966.
-
Campbell MJ, Bustamante-Gomez C, Fu Q, Beenken KE, Reyes-Pardo H, Smeltzer MS, O'Brien CA. RANKL-mediated osteoclast formation is required for bone loss in a murine model of Staphylococcus aureus osteomyelitis. Bone. 2024 Oct; 187:117181.
-
Henning P, Westerlund A, Horkeby K, Lionikaite V, Nilsson KH, Mov?rare-Skrtic S, Conaway HH, Lerner UH. Vitamin A enhanced periosteal osteoclastogenesis is associated with increased number of tissue-derived macrophages/osteoclast progenitors. J Biol Chem. 2024 06; 300(6):107308.
-
Marques-Carvalho A, Silva B, Pereira FB, Kim HN, Almeida M, Sard?o VA. Oestradiol and osteoclast differentiation: Effects on p53 and mitochondrial metabolism. Eur J Clin Invest. 2024 Jun; 54(6):e14195.
-
Tenshin H, Delgado-Calle J, Windle JJ, Roodman GD, Chirgwin JM, Kurihara N. Osteocytes and Paget's Disease of Bone. Curr Osteoporos Rep. 2024 04; 22(2):266-272.
-
Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18).
-
Wagner BM, Robinson JW, Prickett TCR, Espiner EA, Khosla S, Gaddy D, Suva LJ, Potter LR. Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts. Calcif Tissue Int. 2022 Nov; 111(5):506-518.
-
MacLeod RS, Meyer MB, Xiong J, Cawley KM, Liu Y, Onal M, Benkusky NA, Thostenson JD, Pike JW, O'Brien CA. Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo. PLoS One. 2021; 16(5):e0250974.
-
Conaway HH, Henning P, Lie A, Tuckermann J, Lerner UH. Glucocorticoids employ the monomeric glucocorticoid receptor to potentiate vitamin D3 and parathyroid hormone-induced osteoclastogenesis. FASEB J. 2019 12; 33(12):14394-14409.
-
Persson E, Souza PPC, Floriano-Marcelino T, Conaway HH, Henning P, Lerner UH. Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor. Front Immunol. 2019; 10:1164.
-
Li JY, Yu M, Tyagi AM, Vaccaro C, Hsu E, Adams J, Bellido T, Weitzmann MN, Pacifici R. IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production. J Bone Miner Res. 2019 02; 34(2):349-360.
-
Lionikaite V, Westerlund A, Conaway HH, Henning P, Lerner UH. Effects of retinoids on physiologic and inflammatory osteoclastogenesis in vitro. J Leukoc Biol. 2018 12; 104(6):1133-1145.
-
Delgado-Calle J, Hancock B, Likine EF, Sato AY, McAndrews K, Sanudo C, Bruzzaniti A, Riancho JA, Tonra JR, Bellido T. MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production. FASEB J. 2018 05; 32(5):2878-2890.
-
Davis HM, Pacheco-Costa R, Atkinson EG, Brun LR, Gortazar AR, Harris J, Hiasa M, Bolarinwa SA, Yoneda T, Ivan M, Bruzzaniti A, Bellido T, Plotkin LI. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 2017 06; 16(3):551-563.
-
Ye S, Fujiwara T, Zhou J, Varughese KI, Zhao H. LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. Int J Biol Sci. 2016; 12(12):1488-1499.
-
Hoscheit M, Conner G, Roemer J, Vuckovska A, Abbasnia P, Vana P, Shankar R, Kennedy R, Callaci J. Burn Injury Has Skeletal Site-Specific Effects on Bone Integrity and Markers of Bone Remodeling. J Burn Care Res. 2016 Nov/Dec; 37(6):367-378.
-
Fujiwara Y, Piemontese M, Liu Y, Thostenson JD, Xiong J, O'Brien CA. RANKL (Receptor Activator of NF?B Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice. J Biol Chem. 2016 Nov 25; 291(48):24838-24850.
-
Conaway HH, Henning P, Lie A, Tuckermann J, Lerner UH. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity. Bone. 2016 12; 93:43-54.
-
Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016 09 01; 311(3):E587-93.
-
Fujiwara T, Zhou J, Ye S, Zhao H. RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival. Cell Death Dis. 2016 07 21; 7:e2300.
-
Pellegrini GG, Morales CC, Wallace TC, Plotkin LI, Bellido T. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner. Nutrients. 2016 Jul 11; 8(7).
-
Onal M, St John HC, Danielson AL, Pike JW. Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice. J Bone Miner Res. 2016 Feb; 31(2):416-29.
-
Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res. 2016 Mar 01; 76(5):1089-100.
-
Jilka RL, O'Brien CA. The Role of Osteocytes in Age-Related Bone Loss. Curr Osteoporos Rep. 2016 Feb; 14(1):16-25.
-
Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, Bonewald L, Manolagas SC, O'Brien CA. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One. 2015; 10(9):e0138189.
-
Kim HN, Han L, Iyer S, de Cabo R, Zhao H, O'Brien CA, Manolagas SC, Almeida M. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs. Mol Endocrinol. 2015 Oct; 29(10):1498-509.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|